Pharmacokinetics (PK) study of meropenem in Epithelial Lining Fluid (ELF), an open-label study
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Meropenem (Primary)
- Indications Bacterial infections; Community-acquired pneumonia; Febrile neutropenia; Skin and soft tissue infections
- Focus Pharmacokinetics
- 06 Jul 2019 Status changed from completed to active, no longer recruiting.
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 17 Feb 2016 Status changed from recruiting to active, no longer recruiting.